FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Ovarian Cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Second surgery may not benefit women with recurrent ovarian cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: Women with recurrent ovarian cancer
Many women who have recurrent ovarian cancer have a second surgery. A new study suggests that women with platinum sensitive cancers who get chemotherapy alone may do as well as or better than women who have surgery followed by chemotherapy. (1/21/20)
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer
Relevance: High
Strength of Science: High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women newly-diagnosed with ovarian cancer
This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)
Read MoreStudy : Supportive care can improve quality of life for people with metastatic breast cancer
Most relevant for: People diagnosed with metastatic breast cancer
Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : LGBTQ patients recommend improvements for their cancer care
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: LGBTQ cancer patients and their healthcare providers.
Very little research has focused on the cancer care experiences of lesbian, gay, bisexual, transgender and queer (LGBTQ) people. This study looks at recommendations from the LGBTQ community for improving their cancer care. (6/20/19)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Prevalence of BRCA founder mutations in Bahamian women
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Bahamanian women
The Bahamas has the highest known frequency of BRCA mutations among people diagnosed with breast cancer. This study reviewed whether population-based BRCA testing (testing everyone regardless of family or personal history of cancer) would be an effective approach for finding mutation carriers in the Bahamas. (3/4/19)
Read MoreArticle : Promise of a cure for cancer is too good to be true
Most relevant for: People diagnosed with cancer
The Jerusalem Post published an article titled, “A cure for cancer? Israeli scientists may have found one.” The story profiled a small Israeli company called Accelerated Evolution Biotechnologies that has been working on developing new cancer treatments since 2000. The article relied almost entirely on an interview with the company’s chairperson of the board who made a series of unsubstantiated claims that included that, in a year’s time, the company will offer a complete cure for cancer. (2/12/19)
Read MoreArticle : The cost of cancer care and impact of financial hardship on treatment
Most relevant for: Anyone diagnosed with cancer
Several recent studies on the cost of cancer care show the negative effects on cancer patients. We review an article by Kaiser Health News and associated studies about the financial impact of breast cancer treatment and cost of precision medicine. (2/8/19)
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Can population-based DNA sequencing find more people at risk for hereditary cancers?
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women over age 30
It is well documented that many BRCA mutation carriers are missed using current family history-based screening approaches. As a result, experts are beginning to call for population-based BRCA genetic testing—an organized effort to screen all women like we do for breast and cervical cancer. A recent study looked at whether a population-based genetic testing approach would better identify mutation carriers compared with current practice. (11/17/18)
Read MoreArticle : The importance of racial diversity in clinical trials
Most relevant for: People who are a member of a racial or ethnic minority group
This article by journalists Caroline Chen and Riley Wong looks at racial disparities between participation in clinical trials and the population of people with cancer. (11/6/18)
Este artículo está disponible en español.
Read MoreRelevance: Medium-Low
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : A new method for determining whether genetic variants in BRCA1 increase cancer risk
Relevance: Medium-Low
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People who have a Variant of Uncertain Significance in a gene associated with cancer risk.
Ever since BRCA1 was discovered, researchers have been trying to understand which of the thousands of possible DNA changes in this gene increase cancer risk and which are harmless changes. A new study in Nature reports how a cutting-edge technology called “genome editing” may be used to classify changes—known as variants of uncertain significance-in BRCA1 as harmful or harmless. Once validated, this same technology may be used to classify variants in other genes. (9/29/18)
Read MoreSearch XRAY studies and Articles
This Portal Sponsored By: